LungOI Is Among The First AI-based Tests To Receive a Medicare Payment Rate.
ImageneOI is the first NSCLC genomic profiling AI tool on the Sectra Amplifier Marketplace.
Rapid NSCLC Biomarker Test already demonstrated its significant impact and clinical benefits as part of a lung cancer clinical study.
Leveraging AI-based molecular profiling from a digitized biopsy image to enable physicians to gain immediate oncology intelligence.
The ImageneOI rapid AI-based biomarker profiling platform significantly improves lung cancer patient outcomes, as demonstrated by a recently published case report.
Visionaries and Experts, Each Having Played a Historical Role in Advancing Precision Oncology Into Current Clinical Practice
A groundbreaking case report publication on the impact of rapid molecular testing on lung cancer patients
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry
The research done by Imagene and Sheba Medical Center was recently published in 'Modern Pathology' journal.
The research will be presented at the European Congress of Pathology (ECP) 2022